Market: NASD |
Currency: USD
Address: 3000 Pegasus Park Drive
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Show more
📈 Taysha Gene Therapies, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$8.67
-
Upside/Downside from Analyst Target:
188.89%
-
Broker Call:
23
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2025-11-13
-
EPS Estimate:
-0.09
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Taysha Gene Therapies, Inc.
| Date | Reported EPS |
|---|
| 2025-11-13 (estimated upcoming) | - |
| 2025-08-12 | -0.08 |
| 2025-05-15 | -0.07 |
| 2025-02-26 | -0.07 |
| 2024-11-13 | -0.07 |
| 2024-08-12 | -0.09 |
| 2024-05-14 | -0.1 |
| 2024-03-19 | -0.28 |
| 2023-11-14 | -0.93 |
| 2023-08-14 | -0.38 |
| 2023-05-11 | -0.28 |
| 2023-03-28 | -0.34 |
| 2022-11-08 | -0.64 |
| 2022-08-11 | -0.84 |
| 2022-05-16 | -1.31 |
| 2022-03-31 | -1.32 |
| 2021-11-10 | -1.35 |
| 2021-08-16 | -1.09 |
| 2021-05-11 | -0.87 |
| 2021-03-03 | -0.31 |
| 2020-11-12 | -1.28 |
📰 Related News & Research
No related articles found for "taysha gene".
